Skip to main navigation menu Skip to main content Skip to site footer

Vol. 11 No. 02 (2024)
International Multidisciplinary Journal for Research & Development (IMJRD)

Articles

BETTA BLOCKER ASSIGNMENT FOR PATIENTS WITH METABOLIC DISORDERS

Published 2024-02-29

  • Xudoyarova N.K.

Xudoyarova N.K.
Assistant of the department of “Internal medicine” Andijon State Medical Institute Uzbekistan,Andijon

Abstract

A metabolic disorder is a disorder that negatively alters the body's processing and distribution of macronutrients, such as proteins, fats, and carbohydrates. Metabolic disorders can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

Keywords

Betta blockers, Metabolic disorder, hypertension, sympathetic nervous system, hyperinsulinemia, myocardial infarction, nebivalol.

DOWNLOAD PDF CERTIFICATE

References

  1. Kannel W.B., McGee D.L. Diabetes and cardiovascular risk factors: the Framingham Study // Circulation. 1979. Vol. 59. № 1. P. 8–13.
  2. Haffner S., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. № 4. P. 229–234.
  3. Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of innate immune system? // Diabetologia. 1998. Vol. 41. № 10. P. 1241–1248.
  4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38 // Br Med J. 1998. Vol. 317. № 7160. P. 703–713.
  5. Jonas M., Reicher-Reiss H., Boyko V., Shotan A., Mandelzweig L., Goldbourt U., Behar S. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group // Am. J. Cardiol. 1996. Vol. 77. № 15. P. 1273–1277.
  6. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group // Lancet. 1986. Vol. 2. № 8498. P. 57–66.
  7. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial // Eur. Heart J. 1985. Vol. 6. № 3. P. 199–226.
  8. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F., Waldenström A., Waldenström J., Wedel H., Wilhelmsen L., Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomized trial // Lancet. 1981. Vol. 2. № 8251. P. 823–827.
  9. Cleophas T.J. Experimental evidence of selective antagonistic action of Nebivolol on β1-adrenergic receptors // J. Clin. Med. 1998. Vol. 2. P. 1–8.
  10. Van Nueten J.M. et al. In vitro pharmacological profile of R065824, a potent and selective β1-adrenergic antagonist // JRF Preclinical Research Report R065834/8. November 1985.
  11. Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A., Toman J., Bohm M., Anker S.D., Thompson S.G., Poole-Wilson P.A. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patient with heart failure (SENIORS) // Eur Heart J. 2005. Vol. 26. № 3. P. 215–225.
  12. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P., Dupont A.G., Van Nueten L., Wooding S.J., Ritter J.M. Nebivolol vasodilates human forearm vasculature: evidence of L-arginine/NO-dependent mechanism // J. Pharmacol. Exp. Ther. 1995. Vol. 274. № 3. P. 1067–1071.
  13. Van de Water A., Janssens W., Van Neuten J., Xhonneux R., De Cree J., Verhaegen H., Reneman R.S., Janssen P.A. Pharmacological and hemodynamic profile of Nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist // J Cardiovasc Pharm. 1988. Vol. 11. № 5. P. 552–563.
  14. Janssens W.J., Geyskens D., Proost F. Comparison of the β-adrenergic antagonistic effects of Nebivolol, carvedilol, celiprolol and bisoprolol on isolated right atria and trachea of the guinea-pig. Preclinical Research Report. June 1996.
  15. Chan T.Y., Woo K.S., Nicholls M.G. The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study // Int. J. Cardiol. 1992. Vol. 35. № 3. P. 387–395.

Downloads

Download data is not yet available.